生命科学资讯

Shrinking TTM Loss At 10x Genomics (TXG) Tests Bearish Earnings Narratives - simplywall.st

'It's really a dire time for patients': Biohaven CEO says FDA red tape is blocking access to rare disease treatments

FDA rejects Disc's rare disease drug despite commissioner's voucher

From sample to insight: Streamlining analysis with the Illumina 5-base solution - Illumina

Illumina completes acquisition of SomaLogic from Standard BioTools - BizWest

Expert Outlook: 10x Genomics Through The Eyes Of 10 Analysts - Benzinga

With the FDA's Moderna decision, vaccine makers face increasingly uncertain regulatory environment

FDA clears Encora Therapeutics’ wearable wrist device for essential tremor

What were the biggest clinical trial flops of 2025?

After R&D head exits, Immunocore CEO pairs ambition with caution for growing cancer portfolio

BofA Maintains Hold Rating on Agilent Technologies (A) After Q2 Report - MSN

Gilead gets cancer drug from China-based Genhouse for $80M upfront

Pentagon adds, then withdraws, WuXi AppTec to Chinese military list

Vertex’s CRISPR therapy rebounds in latest earnings

Why Is 10x Genomics (TXG) Stock Soaring Today - Finviz

Lilly appeals retatrutide classification ruling in case that could impact compounders

Holiday notice

In the clinic for Feb. 13, 2026

Other news to note for Feb. 13, 2026

Regulatory actions for Feb. 13, 2026